About eribulin mesylate
Microtubule inhibitor chemotherapy
Used for
- Unresectable or metastatic breast cancer after prior chemotherapy.
- Unresectable or metastatic liposarcoma after prior anthracycline treatment.
Usual adult dose
1.4 mg/m² intravenously over 2–5 minutes on days 1 and 8 of each 21-day cycle; dose adjustments may be needed.
Common side effects
- Low blood-cell counts, especially neutropenia
- Tiredness and weakness
- Nausea and constipation
- Peripheral neuropathy
Important warnings
- Can cause severe neutropenia and serious infections.
- May cause peripheral neuropathy; treatment interruption or dose reduction may be needed.
- Can prolong the QT interval and affect heart rhythm.
- Requires dose adjustment in liver impairment; monitor blood counts.
Pregnancy
May harm an unborn baby. Pregnancy testing and effective contraception are recommended during treatment and for 2 weeks afterward.
Breastfeeding
Breastfeeding is not recommended during treatment and for 2 weeks after the final dose.
Interactions
- QT-prolonging medicines may increase heart-rhythm risks.
- Medicines that cause low blood-cell counts may increase bone-marrow suppression.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.